Physician profile
Mark Griffin
NPI 1164416251
$7,166.46
in general payments reported to CMS, 2019-2025
34 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $835 · 2021: $947 · 2022: $1,488 · 2023: $1,127 · 2024: $988 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,947.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180.00 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,063.59 | 2019-2025 | |
| Janssen Biotech, INC. | $1,266.14 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $669.43 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $434.37 | 2019-2023 | Axios |
| Janssen Scientific Affairs, LLC | $351.15 | 2019-2023 | Stelara |
| Gilead Sciences, INC. | $306.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.19 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $233.50 | 2022-2025 | |
| Pfizer INC. | $160.82 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $156.43 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $149.23 | 2024-2025 | Dupixent |
| Olympus America INC. | $142.61 | 2019-2020 | |
| Celltrion USA INC. | $140.24 | 2025 | Zymfentra, Vegzelma |
| Celgene Corporation | $104.42 | 2021-2023 | Zeposia |
| Amgen INC. | $98.78 | 2021-2025 | Uplizna, Amjevita, Avsola |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.61 | 2021 | |
| Intercept Pharmaceuticals, INC. | $64.27 | 2022-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $62.02 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $60.60 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $57.06 | 2020-2023 | Linzess |
| Madrigal Pharmaceuticals | $41.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $31.84 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $30.98 | 2022 | |
| Ucb, INC. | $26.08 | 2019-2024 | Cimzia |
| Ipsen Biopharmaceuticals, INC | $25.49 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $23.94 | 2020-2022 | |
| Daiichi Sankyo INC. | $23.34 | 2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Allergan, INC. | $14.21 | 2020 | |
| Lilly USA, LLC | $13.71 | 2024 | Omvoh |
| Medtronic, INC. | $13.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| Organon LLC | $7.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.